NEW YORK (GenomeWeb) – Cambridge Epigenetix and NuGen Technologies have partnered to integrate Cambridge's TrueMethyl technology for oxidative bisulfite sequencing with NuGen's sequencing library preparation kits.

The companies said that the agreement will enable Cambridge to focus on its epigenetic biomarker discovery programs, both in house and in partnership with biopharma companies, while strengthening NuGen's whole-genome and targeted enrichment systems for epigenetic sequencing.